Effect of cannabidiol on sepsis-induced motility disturbances in mice: Involvement of CB1 receptors and fatty acid amide hydrolase

Neurogastroenterology and Motility

Volumn 20, Issue 8, 2008, Pages 919-927

  De Filippis, D ^b   Iuvone, T ^b   D'Amico, A ^b   Esposito, G ^c   Steardo, L ^c   Herman, A G ^d   Pelckmans, P A ^a   De Winter, B Y ^a   De Man, J G ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Cannabidiol; Endocannabinoid system; Fatty acid amide hydrolase; Septic ileus

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG USE; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TRANSIT; ILEUS; INTESTINE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; STOMACH EMPTYING; UPREGULATION;

AMIDOHYDROLASES; ANIMALS; CANNABIDIOL; CAPSAICIN; GASTRIC EMPTYING; GASTROINTESTINAL MOTILITY; INTESTINE, SMALL; LIPOPOLYSACCHARIDES; MALE; MICE; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SENSORY SYSTEM AGENTS; SEPSIS;

EID: 46249121074     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01114.x     Document Type: Article

References (54)

1. Cunha JM, Carlini EA, Pereira AE et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980 21 : 175 85.
2. Malfait AM, Gallily R, Sumariwalla PF et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 2000 97 : 9561 6.
3. Mechoulam R, Parker LA, Gallily R. Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 2002 42 : 11S 9S.
4. Hayakawa K, Mishima K, Abe K et al. Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 2004 15 : 2381 5.
5. Iuvone T, Esposito G, Esposito R, Santamaria R, Di Rosa M, Izzo AA. Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem 2004 89 : 134 41.
6. Sacerdote P, Martucci C, Vaccani A et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 2005 159 : 97 105.
7. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007 556 : 75 83.
8. Rajesh M, Mukhopadhyay P, Batkai S et al. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol 2007 293 : H610 9.
9. Durst R, Danenberg H, Gallily R et al. Cannabidiol, a non-psychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol 2007 293 : H3602 7.
10. Thomas BF, Gilliam AF, Burch DF, Roche MJ, Seltzman HH. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998 285 : 285 92.
11. Bisogno T, Hanus L, De Petrocellis L et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001 134 : 845 52.
12. Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 2005 144 : 1032 6.
13. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 2007 26 : 843 51.
14. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006 58 : 389 462.
15. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998 95 : 8268 73.
16. Ryan D, Drysdale AJ, Pertwee RG, Platt B. Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. Eur J Neurosci 2007 25 : 2093 102.
17. Bisogno T, De Petrocellis L, Di Marzo V. Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr Pharm Des 2002 8 : 533 47.
18. Watanabe K, Kayano Y, Matsunaga T, Yamamoto I, Yoshimura H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol Pharm Bull 1996 19 : 1109 11.
19. Massi P, Valenti M, Vaccani A et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008 104 : 1091 100.
20. Massa F, Marsicano G, Hermann H et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004 113 : 1202 9.
21. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006 20 : 568 70.
22. Kimball ES, Schneider CR, Wallace NH, Hornby PJ. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol 2006 291 : G364 71.
23. D'Argenio G, Petrosino S, Gianfrani C et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 2007 85 : 523 30.
24. Moore FA. The role of the gastrointestinal tract in postinjury multiple organ failure. Am J Surg 1999 17 : 449 53.
25. De Winter BY, van Nassauw L, De Man JG et al. Role of oxidative stress in the pathogenesis of septic ileus in mice. Neurogastroenterol Motil 2005 17 : 251 61.
26. De Filippis D, Iuvone T, Esposito G et al. Melatonin reverses LPS-induced gastro-intestinal motility disturbances through the inhibition of oxidative stress. J Pineal Res 2008 44 : 45 51.
27. Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med 2006 84 : 253 8.
28. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006 399 : 91 5.
29. Esposito G, Scuderi C, Savani C et al. Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 2007 151 : 1272 9.
30. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J 1998 12 : 1035 44.
31. Wagner JA, Varga K, Kunos G. Cardiovascular actions of cannabinoids and their generation during shock. J Mol Med 1998 76 : 824 36.
32. Maccarrone M, De Petrocellis L, Bari M et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 2001 393 : 321 8.
33. Di Marzo V, Bisogno T, De Petrocellis L et al. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur J Biochem 1999 264 : 258 67.
34. Seerden TC, De Man JG, Holzer P et al. Experimental pancreatitis disturbs gastrointestinal and colonic motility in mice: effect of the prokinetic agent tegaserod. Neurogastroenterol Motil 2007 19 : 856 64.
35. De Man JG, Boeckx S, Anguille S et al. Functional study on TRPV1-mediated signalling in the mouse small intestine: involvement of tachykinin receptors. Neurogastroenterol Motil doi
36. De Winter BY, Bredenoord AJ, De Man JG, Moreels TG, Herman AG, Pelckmans PA. Effect of inhibition of inducible nitric oxide synthase and guanylyl cyclase on endotoxin-induced delay in gastric emptying and intestinal transit in mice. Shock 2002 18 : 125 31.
37. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989 249 : 444 9.
38. Fride E, Ponde D, Breuer A, Hanus L. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Neuropharmacology 2005 48 : 1117 29.
39. Izzo AA, Mascolo N, Pinto L, Capasso R, Capasso F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999 384 : 37 42.
40. Izzo AA, Mascolo N, Capasso R, Germano MP, De Pasquale R, Capasso F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch Pharmacol 1999 360 : 221 3.
41. Izzo AA, Fezza F, Capasso R et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001 134 : 563 70.
42. Mascolo N, Izzo AA, Ligresti A et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J 2002 16 : 1973 5.
43. Mathison R, Ho W, Pittman QJ, Davison JS, Sharkey KA. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004 142 : 1247 54.
44. Yuece B, Sibaev A, Broedl UC et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterol Motil 2007 19 : 744 53.
45. Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol 2007 150 : 613 23.
46. Pertwee RG. The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin. Br J Pharmacol 2007 152 : 583 93.
47. Maccarrone M, Fiorucci L, Erba F, Bari M, Finazzi-Agrò A, Ascoli F. Human mast cells take up and hydrolyze anandamide under the control of 5-lipoxygenase and do not express cannabinoid receptors. FEBS Lett 2000 468 : 176 80.
48. Capasso R, Matias I, Lutz B et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005 129 : 941 51.
49. Tanaka M, Yanagihara I, Takahashi H, Hamaguchi M, Nakahira K, Sakata I. The mRNA expression of fatty acid amide hydrolase in human whole blood correlates with sepsis. J Endotoxin Res 2007 13 : 35 8.
50. Liu J, Batkai S, Pacher P et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-kappaB independently of platelet-activating factor. J Biol Chem 2003 278 : 45034 9.
51. Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut 2006 55 : 1373 6.
52. Sanger GJ. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 2007 152 : 663 70.
53. Kohro S, Imaizumi H, Yamakage M et al. Anandamide absorption by direct hemoperfusion with polymixin B-immobilized fiber improves the prognosis and organ failure assessment score in patients with sepsis. J Anesth 2006 20 : 11 6.
54. Costa B, Giagnoni G, Franke C, Trovato AE, Colleoni M. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br J Pharmacol 2004 143 : 247 50.